Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model.
Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model.
复制标题
西咪替丁作为免疫调节剂：慢性皮肤粘膜念珠菌病作为模型。
DOI：
10.7326/0003-4819-92-2-192
复制
发表时间：
1980
影响因子：
39.2
通讯作者：
A. Olansky
中科院分区：
文献类型：
--
作者：
J. Jorizzo;W. Sams;B. Jegasothy;A. Olansky
对四名患有慢性皮肤粘膜念珠菌病的成人患者进行了研究，以确定西咪替丁作为免疫调节剂的可能作用。这些患者在体内和体外对念珠菌抗原的基线细胞免疫应答为阴性，通过皮内皮肤试验、淋巴细胞转化和对西咪替丁产生白细胞移动抑制因子，300 mg口服，每天4次。随后，四名患者中有四名患者出现了强烈的皮内试验反应(大于15 mm)，四名患者中有两名产生了针对念珠菌抗原的白细胞迁移抑制因子。停止治疗4周后，皮肤试验和白细胞移动抑制因子的产生恢复到基线负值。在额外服用西咪替丁4周后，4名患者中有4名患者的皮肤试验呈强阳性，并对念珠菌抗原产生了白细胞移动抑制因子。治疗对淋巴细胞转化无影响。
Four adult patients with chronic mucocutaneous candidiasis were studied to establish a possible role for cimetidine as an immunomodulator. These patients had negative baseline in-vivo and in-vitro cell-mediated immune response to candida antigen as measured by intradermal skin tests, lymphocyte transformation, and leukocyte migration inhibitory factor production to cimetidine, 300 mg by mouth, four times daily. Subsequently four of four patients developed strong (greater than 15 mm) intradermal skin test reactions, and two of four patients produced leukocyte migration inhibitory factor to candida antigen. Skin tests and leukocyte migration inhibitory factor production reverted to baseline negative values when repeated 4 weeks after discontinuation of therapy. After 4 additional weeks on cimetidine, four of four patients showed strong positive skin tests and leukocyte migration inhibitory factor production to candida antigen. Lymphocyte transformation was not affected by therapy.